With the development of effective therapies against HIV, chronic HCV infection has become a major cause of morbidity and mortality among patients harboring both infections. Therefore, fibrosis stage assessment and consideration of HCV treatment options is of utmost importance in this particular patient group. Over the last years, treatment with pegylated interferon (IFN) plus ribavirin (RBV) has been recommended for co-infected patients who are at the greatest risk for liver disease progression, however, despite acceptable response rates for HCV genotype 2 and 3 patients, the effectiveness of HCV treatment in the widespread genotype 1 and 4 patients has been disappointing.
展开▼
